Fred Hutch Pancreatic cancer researcher Dr. Sunil Hingorani has won a three-year, $1.8 million grant from the federal Cancer Moonshot program, the signature initiative of former Vice President Joseph Biden. Hingorani is one of six collaborators nationwide who received funding this fall for a new research consortium focused on the biological context of pancreatic tumors — such as nearby immune cells or blood vessels — which can have a major impact on a tumor’s vulnerability to treatment.
Fred Hutchinson Cancer Research Center bioengineer and cancer researcher Dr. Cyrus Ghajar has focused much of his work on what causes breast cancer cells to metastasize. Now, with the help of a new $1 million grant from the W.M. Keck Foundation, Ghajar and his team are hoping to crack open a mystery that has long puzzled scientists in the field: Why do metastatic cells, which can proliferate in many organs, nearly always fail to grow in skeletal muscles, which account for as much as half the body mass of an adult?
First extensive immune profiling of sarcomas shows some types may be susceptible to immunotherapy; Fred Hutch hosts first-of-its-kind regional conference for science communicators; and Pathway that regulates organ size may also underlie tumors’ resistance to certain chemotherapy drugs.
A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study
April 24, 2017
| By Sabrina Richards / Fred Hutch News Service
A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.